Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation
View/ Open
Author
Golay, H. G.
Koyama, S.
Harden, M.
Rojas-Rudilla, V.
Chevalier, A.
Thai, T.
Lydon, C.
Mach, S.
Wong, J. A.
Rabin, A. R.
Helmkamp, J.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1158/2326-6066.CIR-15-0024Metadata
Show full item recordCitation
Van Allen, E. M., H. G. Golay, Y. Liu, S. Koyama, K. Wong, A. Taylor-Weiner, M. Giannakis, et al. 2015. “Long-Term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.” Cancer Immunology Research 3 (8) (May 26): 855–863. doi:10.1158/2326-6066.cir-15-0024.Abstract
PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. We performed comprehensive genomic profiling on a tumor and germline sample from a patient with refractory lung adenocarcinoma who achieved marked long-term clinical benefit from anti-PD-L1 therapy. We discovered activating somatic and germline amino acid variants in JAK3 that promoted PD-L1 induction in lung cancer cells and in the tumor immune microenvironment. These findings suggest that genomic alterations that deregulate cytokine receptor signal transduction could contribute to PD-L1 activation and engagement of the PD-1 immune checkpoint in lung cancer.Other Sources
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527885/Terms of Use
This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAPCitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:32706163
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)